Dr. Moskovits is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 E 34th St
New York, NY 10016Phone+1 212-731-5196Fax+1 917-829-2037
Summary
- Dr. Tibor Moskovits is an oncologist based in New York, NY, specializing in hematologic oncology, general/benign hematology, and myeloproliferative disease. His medical education includes a residency in internal medicine at the Icahn School of Medicine at Mount Sinai/Beth Israel and fellowships in hematology and medical oncology at NYU Grossman School of Medicine. Dr. Moskovits has contributed to several publications, with notable works on impaired humoral immunity in Non-Hodgkin Lymphoma and microbial dysbiosis in aggressive B-cell non-Hodgkin lymphoma. His accolades include multiple appearances on the Top Doctors lists by Castle Connolly and New York Magazine, among others.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1991 - 1992- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1989 - 1991
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1985 - 1989
State University of New York Downstate Medical Center College of MedicineClass of 1985
Certifications & Licensure
NY State Medical License 1986 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- New York Magazine: Top Doctors Castle Connolly, 2003, 2006-2007
- Join now to see all
Publications & Presentations
PubMed
- Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.Gaurav Varma, Lindsay Fogel, Beth Gordon, Mateo Mejia Saldarriaga, Jaeil Ahn
Leukemia & Lymphoma. 2025-01-05 - 18 citationsImpaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL PatientsCatherine Diefenbach, Jessica Caro, Akiko Koide, Michael L. Grossbard, Judith D. Goldberg
Medrxiv. 2021-06-03 - 18 citationsMicrobial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphomaCatherine Diefenbach, Brandilyn A. Peters, Huilin Li, Bruce Raphael, Tibor Moskovits
Blood Advances. 2021-03-09
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
